IL-13 effector functions

Annual Review of Immunology

Volumn 21, Issue , 2003, Pages 425-456

  Wynn, Thomas A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Asthma; Cancer; Fibrosis; IL 4; Parasite

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON MONOCLONAL ANTIBODY; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 13 INHIBITOR; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NEUTRALIZING INTERLEUKIN 13 MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; PROTEIN INHIBITOR; RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE;

AIRWAY; ALLERGIC ASTHMA; ALLERGY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHMA; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EOSINOPHIL; EXTRACELLULAR MATRIX; FIBROSIS; GASTROINTESTINAL INFECTION; HODGKIN DISEASE; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INFECTION RESISTANCE; INFLAMMATION; INHIBITION KINETICS; KNOCKOUT MOUSE; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LISTERIA MONOCYTOGENES; LUNG; MONOCYTE; MUCUS SECRETION; NEMATODIASIS; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SCHISTOSOMIASIS; TUMOR GROWTH; UPREGULATION; ANIMAL; GASTROINTESTINAL DISEASE; IMMUNOLOGY; LUNG INFECTION; MOUSE; NEOPLASM; RESPIRATORY TRACT ALLERGY;

ANIMALS; ASTHMA; CYTOKINES; FIBROSIS; GASTROINTESTINAL DISEASES; HUMANS; INTERLEUKIN-13; LUNG DISEASES, PARASITIC; MICE; NEMATODE INFECTIONS; NEOPLASMS; RESPIRATORY HYPERSENSITIVITY;

EID: 0037775352     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.21.120601.141142     Document Type: Review

References (189)

1. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, et al. 1993. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248-50
2. McKenzie AN, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J, et al. 1993. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc. Natl. Acad. Sci. USA 90:3735-40
3. Punnonen J, Aversa G, Cocks BG, McKenzie ANJ, Menon S, et al. 1993. Interleukin 13 induces intefieukin 4-independent IgG4 and IgE synthesis and CD23 expression in human B cells. Proc. Natl. Acad. Sci. USA 90:3730-34
4. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. 1996. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4:313-19
5. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, et al. 1996. Essential role of Stat6 in IL-4 signalling. Nature 380:627-30
6. Noben-Trauth N, Shultz LD, Brombacher F, Urban IF Jr, Gu H, et al. 1997. An interleukin 4 (IL-4)-independent pathway for CD4 + T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc. Natl. Acad. Sci. USA 94:10838-43
7. Barner M, Mohrs M, Brombacher F, Kopf M. 1998. Differences between IL-4R alpha-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr. Biol. 8:669-72
8. Urban JF Jr, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, et al. 1998. IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 8:255-64
9. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, et al. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-88
10. Emson CL, Bell SE, Jones A, Wisden W, McKenzie AN. 1998. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J. Exp. Med. 188:399-404
11. McKenzie GJ, Bancroft A, Grencis RK, McKenzie AN. 1998. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr. Biol. 8:339-42
12. McKenzie GJ, Emson CL, Bell SE, Anderson S, Fallon P, et al. 1998. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 9:423-32
13. McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie AN. 1999. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J. Exp. Med. 189:1565-72
14. Debinski W, Obiri NI, Pastan I, Puri RK. 1995. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270:16775-80
15. Donaldson DD, Whiners MJ, Fitz LJ, Neben TY, Finnerty H, et al. 1998. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL- 13 receptor alpha 1. J. Immunol. 161:2317-24
16. Ruth JH, Warmington KS, Shang X, Lincoln P, Evanoff H, et al. 2000. Interleukin 4 and 13 participation in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation: multiparameter analysis of cellular recruitment, chemokine expression and cytokine networks. Cytokine 12:432-44
17. Guo L, Hu-Li J, Zhu J, Parmetier C, Watson C, et al. 2001. Disrupting I113 impairs production of IL-4 specified by the linked allele. Nat. Immunol. 2:461-66
18. Finkelman FD, Shea-Donohue T, Goldhill J, Sullivan CA, Morris SC, et al. 1997. Cytokine regulation of host defense against parasitic gastrointestinal nematodes: lessons from studies with rodent models. Annu. Rev. Immunol. 15:505-33
19. Katona IM, Urban JF Jr, Finkelman FD. 1988. The role of L3T4+ and Lyt-2+ T cells in the IgE response and immunity to Nippostrongylus brasiliensis. J. Immunol. 140:3206-11
20. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmarm H, et al. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362:245-48
21. Madden KB, Urban JF Jr, Ziltener HJ, Schrader JW, Finkelman FD, et al. 1991. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J. Immunol. 147:1387-91
22. Urban IF Jr, Maliszewski CR, Madden KB, Katona IM, Finkelman FD. 1995. IL-4 treatment can cure established gastrointestinal nematode infections in immunocompetent and immunodeficient mice. J. Immunol. 154:4675-84
23. Urban JF Jr, Noben-Trauth N, Schopf L, Madden KB, Finkelman FD. 2001. Cutting edge: IL-4 receptor expression by non-bone marrow-derived cells is required to expel gastrointestinal nematode parasites. J. Immunol. 167:6078-81
24. Grencis RK. 2001. Cytokine regulation of resistance and susceptibility to intestinal nematode infection - from host to parasite. Vet. Parasitol. 100:45-50
25. Finkelman FD, Wynn TA, Donaldson DD, Urban JF Jr. 1999. The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections. Curr. Opin. Immunol. 11:420-26
26. Bancroft AJ, McKenzie AN, Grencis RK. 1998. A critical role for IL-13 in resistance to intestinal nematode infection. J. Immunol. 160:3453-61
27. Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK. 2000. Gastrointestinal nematode expulsion in IL-4 knockout mice is IL-13 dependent. Eur. J. Immunol. 30:2083-91
28. Artis D, Humphreys NE, Bancroft AJ, Rothwell NJ, Potten CS, et al. 1999. Tumor necrosis factor alpha is a critical component of interleukin 13-mediated protective T helper cell type 2 responses during helminth infection. J. Exp. Med. 190:953-62
29. Urban J, Fang H, Liu Q, Ekkens MJ, Chen SJ, et al. 2000. IL-13-mediated worm expulsion is B7 independent and IFN-gamma sensitive. J. Immunol. 164:4250-56
30. Urban IF Jr, Schopf L, Morris SC, Orekhova T, Madden KB, et al. 2000. Stat6 signaling promotes protective immunity against Trichinella spiralis through a mast cell- and T cell-dependent mechanism. J. Immunol. 164:2046-52
31. Khan WI, Vallance BA, Blennerhassett PA, Deng Y, Verdu EF, et al. 2001. Critical role for signal transducer and activator of transcription factor 6 in mediating intestinal muscle hypercontractility and worm expulsion in Trichinella spiralis-infected mice. Infect. Immun. 69:838-44
32. Shea-Donohue T, Sullivan C, Finkelman FD, Madden KB, Morris SC, et al. 2001. The role of IL-4 in Heligmosomoides polygyrus-induced alterations in murine intestinal epithelial cell function. J. Immunol. 167:2234-39
33. Schopf LR, Hoffmann KF, Cheever AW, Urban IF Jr, Wynn TA. 2002. IL-10 is critical for host resistance and survival during gastrointestinal helminth infection. J. Immunol. 168:2383-92
34. Khan WI, Blennerhasset P, Ma C, Matthaei KI, Collins SM. 2001. Stat6 dependent goblet cell hyperplasia during intestinal nematode infection. Parasite Immunol. 23:39-42
35. Akiho H, Blennerhassett P, Deng YK, Collins SM. 2002. Role of IL-4, IL-13, and STAT6 in inflammation-induced hypercontractility of murine smooth muscle cells. Am. J. Physiol. Gastrointest. Liver Physiol. 282:G226-32
36. Madden KB, Whitman L, Sullivan C, Finkelman FD, Gause WC, et al. 2002. Role of Stat6 and mast cells in IL-4-and IL-13-induced alterations in murine intestinal epithelial cell function. J. Immunol. 169:4417-22
37. Zhao A, Mulloy D, Urban IF Jr, Gause WC, Shea-Donohue T 2001. Role of Stat6 in hypercontractility of murine small intestinal smooth muscle induced by nematode infection. Gastroenterology 120:A534
38. Reiner SL, Locksley RM. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-77
39. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194:1497-506
40. Mock B, Blackwell J, Hilgers J, Potter M, Nacy C. 1993. Genetic control of Leishmania major infection in congenic, recombinant inbred and F2 populations of mice. Eur. J. Immunogenet. 20:335-48
41. Beebe AM, Mauze S, Schork NJ, Coffman RL. 1997. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Immunity 6:551-57
42. Demant P, Lipoldova M, Svobodova M. 1996. Resistance to Leishmania major in mice. Science 274:1392-93
43. Noben-Trauth N, Paul WE, Sacks DL. 1999. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J. Immunol. 162:6132-40
44. Sosa MR, Rosas LE, McKenzie AN, Satoskar AR. 2001. IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection. Eur. J. Immunol. 31:3255-60
45. Bourreau E, Prevot G, Pradinaud R, Launois P. 2001. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. J. Infect. Dis. 183:953-59
46. Babaloo Z, Kaye PM, Eslami MB. 2001. Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans. R Soc. Trop. Med. Hyg. 95:85-88
47. Kopf M, Brombacher F, Kohler G, Kienzle G, Widmann KH, et al. 1996. IL-4-deficient Balb/c mice resist infection with Leishmania major. J. Exp. Med. 184:1127-36
48. Mohrs M, Ledermann B, Kohler G, Dorfmuller A, Gessner A, et al. 1999. Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J. Immunol. 162:7302-8
49. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, et al. 2000. IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 164:1458-62
50. Dent AL, Doherty TM, Paul WE, Sher A, Staudt LM. 1999. BCL-6-deficient mice reveal an IL-4-independent, STAT6-dependent pathway that controls susceptibility to infection by Leishmania major. J. Immunol. 163:2098-103
51. Alexander J, Brombacher F, McGachy A, Scott P, McKenzie ANJ, et al. 2002. An essential role for IL-13 in maintaining a non-healing response following Leishamani mexicana infection. Eur. J. Immunol. 32:2923-33
52. Gorelik L, Constant S, Flavell RA. 2002. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195:1499-505
53. Flesch IE, Wandersee A, Kaufmann SH. 1997. Effects of IL-13 on murine listeriosis. Int. Immunol. 9:467-74
54. Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, et al. 1999. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J. Immunol. 162:920-30
55. Blease K, Jakubzick C, Westwick J, Lukacs N, Kunkel SL, et al. 2001. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J. Immunol. 166:5219-24
56. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, et al. 1998. Interleukin-13: central mediator of allergic asthma. Science 282:2258-61
57. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, et al. 1998. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261-63
58. Fallon PG, Emson CL, Smith P, McKenzie AN. 2001. IL-13 overexpression predisposes to anaphylaxis following antigen sensitization. J. Immunol. 166:2712-16
59. Come J, Chupp G, Lee CG, Homer RJ, Zhu Z, et al. 2000. IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J. Clin. Invest. 106:783-91
60. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, et al. 2000. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J. Clin. Invest. 106:1081-93
61. Wynn TA, Eltoum I, Oswald IP, Cheever AW, Sher A. 1994. Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J. Exp. Med. 179:1551-61
62. Cohn L, Tepper JS, Bottomly K. 1998. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J. Immunol. 161:3813-16
63. Morse B, Sypek JP, Donaldson DD, Haley KJ, Lilly CM. 2002. Effects of IL-13 on airway responses in the guinea pig. Am. J. Physiol. Lung Cell Mol. Physiol. 282:L44-49
64. Kuperman D, Schofield B, Wills-Karp M, Grusby MJ. 1998. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J. Exp. Med. 187:939-48
65. Akimoto T, Numata F, Tamura M, Takata Y, Higashida N, et al. 1998. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J. Exp. Med. 187:1537-42
66. Cohn L, Homer RJ, MacLeod H, Mohrs M, Brombacher F, et al. 1999. Th2-induced airway mucus production is dependent on IL-4Ralpha, but not on eosinophils. J. Immunol. 162:6178-83
67. Yang M, Hogan SP, Henry PJ, Matthaei KI, McKenzie AN, et al. 2001. Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin. Am. J. Respir. Cell Mol. Biol. 25:522-30
68. Venkayya R, Lam M, Willkom M, Grunig G, Corry DB, et al. 2002. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am. J. Respir. Cell. Mol. Biol. 26:202-8
69. Jordan NJ, Watson ML, Williams RJ, Roach AG, Yoshimura T, et al. 1997. Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br. J. Pharmacol. 122:749-57
70. Wei LH, Jacobs AT, Morris SM Jr, Ignarro LJ. 2000. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 279:C248-56
71. Laporte JC, Moore PE, Baraldo S, Jouvin MH, Church TL, et al. 2001. Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am. J. Respir. Crit. Care Med. 164:141-48
72. Mehlhop PD, van de Rijn M, Goldberg AB, Brewer JP, Kurup VP, et al. 1997. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc. Natl. Acad. Sci. USA 94:1344-49
73. Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, et al. 2000. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J. Immunol. 165:108-13
74. Walter DM, McIntire JJ, Berry G, McKenzie AN, Donaldson DD, et al. 2001. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J. Immunol. 167:4668-75
75. Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, et al. 2001. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J. Allergy Clin. Immunol. 108:594-601
76. Mattes J, Yang M, Mahalingam S, Kuehr J, Webb DC, et al. 2002. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J. Exp. Med. 195:1433-44
77. Mattes J, Yang M, Siqueira A, Clark K, MacKenzie J, et al. 2001. IL-13 induces airways hyperreactivity independently of the IL-4R alpha chain in the allergic lung. J. Immunol. 167:1683-92
78. Blease K, Schuh JM, Jakubzick C, Lukacs NW, Kunkel SL, et al. 2002. Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am. J. Pathol. 160:481-90
79. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, et al. 2002. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med. 8:885-89
80. Puri RK. 1995. Structure and function of interleukin 4 and its receptors. In Cytokines: Interleukins and Their Receptors, ed. R Kurzrock, M Talpaz, pp. 143-85. Norwell, MA: Kluwer
81. Blais Y, Gingras S, Haagensen DE, Labrie F, Simard J. 1996. Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol. Cell Endocrinol. 121:11-18
82. Obiri NI, Husain SR, Debinski W, Puri RK. 1996. Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin. Cancer Res. 2:1743-49
83. Serve H, Oelmann E, Herweg A, Oberberg D, Serve S, et al. 1996. Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res. 56:3583-88
84. Renard N, Duvert V, Banchereau J, Saeland S. 1994. Interleukin-13 inhibits the proliferation of normal and leukemic human B-cell precursors. Blood 84:2253-60
85. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. 2001. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J. Exp. Med. 194:1743-54
86. Lebel-Binay S, Laguerre B, Quintin-Colonna F, Conjeaud H, Magazin M, et al. 1995. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur. J. Immunol. 25:2340-48
87. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. 1998. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J. Immunol. 160:5869-73
88. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, et al. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-20
89. Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF. 2000. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165:6024-28
90. Ostrand-Rosenberg S, Grusby MJ, Clements VK. 2000. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165:6015-19
91. Chaouchi N, Wallon C, Goujard C, Tertian G, Rudent A, et al. 1996. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 87:1022-29
92. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, et al. 1999. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J. Exp. Med. 189:1939-46
93. Lai YH, Mosmann TR. 1999. Mouse IL-13 enhances antibody production in vivo and acts directly on B cells in vitro to increase survival and hence antibody production. J. Immunol. 162:78-87
94. Billard C, Caput D, Vita N, Ferrara P, Orrico M, et al. 1997. Interleukin-13 responsiveness and interleukin-13 receptor expression in non-Hodgkin's lymphoma and reactive lymph node B cells. Modulation by CD40 activation. Eur. Cytokine Netw. 8:19-27
95. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, et al. 2001. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97:250-55
96. Oshima Y, Puri RK. 2001. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist. Cell Immunol. 211:37-42
97. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, et al. 2002. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Steinberg cells of Hodgkin lymphoma. Blood 99:618-26
98. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, et al. 2001. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 38:368-75
99. Debinski W, Karlsson B, Lindholm L, Siegall CB, Willingham MC, et al. 1992. Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. J. Clin. Invest. 90:405-11
100. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, et al. 1996. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87:4333-39
101. Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, et al. 1997. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J. Urol. 158:948-53
102. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. 1995. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res. 1:1253-58
103. Kornmann M, Kleeff J, Debinski W, Korc M. 1999. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer Res. 19:125-31
104. Husain SR, Puri RK. 2000. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 95:3506-13
105. Kawakami K, Kawakami M, Joshi BH, Puri RK. 2001. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 61:6194-200
106. Debinski W, Miner R, Leland P, Obiri NI, Puri RK. 1996. Receptor for interleukin (IL) 13 does not interact with but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271:22428-33
107. Kawakami K, Taguchi J, Murata T, Puri RK. 2001. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97:2673-79
108. Kawakami K, Husain SR, Bright RK, Puri RK. 2001. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 8:861-68
109. Oshima Y, Puri RK. 2001. Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13. J. Biol. Chem. 276:15185-91
110. Debinski W, Gibo DM, Obiri NI, Kealiher A, Puri RK. 1998. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat. Biotechnol. 16:449-53
111. Cheever AW, Williams ME, Wynn TA, Finkelman FD, Seder RA, et al. 1994. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J. Immunol. 153:753-59
112. Cheever AW. 1972. Pipe-stem fibrosis of the liver. Trans. R. Soc. Trop. Med. Hyg. 66:947-48
113. + Th2 response induced by Schistosoma mansoni eggs develops rapidly, through an early, transient, Th0-like stage. J. Immunol. 148:2283-88
114. Wynn TA, Eltoum I, Cheever AW, Lewis FA, Gause WC, et al. 1993. Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J. Immunol. 151:1430-40
115. Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, et al. 1995. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376:594-96
116. Cheever AW, Poindexter RW, Wynn TA. 1999. Egg laying is delayed but worm fecundity is normal in SCID mice infected with Schistosoma japonicum and S. mansoni with or without recombinant tumor necrosis factor alpha treatment. Infect. Immun. 67:2201-8
117. Fallon PG, Dunne DW. 1999. Tolerization of mice to Schistosoma mansoni egg antigens causes elevated type 1 and diminished type 2 cytokine responses and increased mortality in acute infection. J. Immunol. 162:4122-32
118. Brunet LR, Finkelman FD, Cheever AW, Kopf MA, Pearce EJ. 1997. IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis. J. Immunol. 159:777-85
119. Hoffmann KF, Cheever AW, Wynn TA. 2000. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J. Immunol. 164:6406-16
120. Pearce EJ, Cheever A, Leonard S, Covalesky M, Fernandez-Botran R, et al. 1996. Schistosoma mansoni in IL-4-deficient mice. Int. Immunol. 8:435-44
121. Kaplan MH, Whitfield JR, Boros DL, Grusby MJ. 1998. Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. J. Immunol. 160:1850-56
122. Jankovic D, Kullberg MC, Noben-Trauth N, Caspar P, Ward JM, et al. 1999. Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile. J. Immunol. 163:337-42
123. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 104:777-85
124. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA. 2001. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 34:273-82
125. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. 2000. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J. Immunol. 164:2585-91
126. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, et al. 2000. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J. Pharmacol. Exp. Ther. 292:988-94
127. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, et al. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J. Exp. Med. 194:809-21
128. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, et al. 2001. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/ type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-Arginine metabolism. J. Immunol. 167:6533-44
129. Julia V, Hessel EM, Malherbe L, Glaichenhaus N, O'Garra A, et al. 2002. A restricted subset of dendritic cells captures airborne antigens and remains able to activate specific T cells long after antigen exposure. Immunity 16:271-83
130. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. 1995. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25:1101-4
131. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, et al. 1999. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 163:3771-77
132. Hesse M, Cheever AW, Jankovic D, Wynn TA. 2000. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease. Am. J. Pathol. 157:945-55
133. Wallace WA, Ramage EA, Lamb D, Howie SE. 1995. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin. Exp. Immunol. 101:436-41
134. Shirwan H. 1999. Chronic allograft rejection. Do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role? Transplantation 68:715-26
135. Baecher-Allan CM, Barth RK. 1993. PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis. Reg. Immunol. 5:207-17
136. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. 1997. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J. Rheumatol. 24:328-32
137. Westermann W, Schobl R, Rieber EP, Frank KH. 1999. Th2 cells as effectors in postirradiation pulmonary damage preceding fibrosis in the rat. Int. J. Radiat. Biol. 75:629-38
138. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. 1999. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17:701-38
139. Finkelman FD, Morris SC, Orekhova T, Mori M, Donaldson D, et al. 2000. Stat6 regulation of in vivo IL-4 responses. J. Immunol. 164:2303-10
140. Jankovic D, Kullberg MC, Noben-Trauth N, Caspar P, Paul WE, et al. 2000. Single cell analysis reveals that IL-4 receptor/Stat6 signaling is not required for the in vivo or in vitro development of CD4+ lymphocytes with a Th2 cytokine profile. J. Immunol. 164:3047-55
141. Doherty TM, Kastelein R, Menon S, Andrade S, Coffman RL. 1993. Modulation of murine macrophage function by IL-13. J. Immunol. 151:7151-60
142. de Vries JE. 1998. The role of IL-13 and its receptor in allergy and inflammatory responses. J. Allergy Clin. Immunol. 102:165-69
143. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, et al. 2001. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107:963-70
144. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, et al. 1993. Natural killer cell stimulatory factor (Interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199-204
145. Wynn TA, Jankovic D, Hieny S, Zioncheck K, Jardieu P, et al. 1995. IL-12 exacerbates rather than suppresses T helper 2-dependent pathology in the absence of endogenous IFN-gamma. J. Immunol. 154:3999-4009
146. Finkelman FD, Madden K, Cheever A, Katona IM, Morris SC, et al. 1994. Effects of interleukin-12 on immune responses and host protection in mice infected with intestinal nematode parasites. J. Exp. Med. 179:1563-72
147. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, et al. 1995. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J. Exp. Med. 182:1527-36
148. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, et al. 1998. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160:2555-59
149. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, et al. 1999. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol. 162:6284-93
150. Krieg AM. 1999. CpG DNA: a novel immunomodulator. Trends Microbiol. 7:64-65
151. Ford JG, Rennick D, Donaldson DD, Venkayya R, McArthur C, et al. 2001. Il-13 and IFN-gamma: interactions in lung inflammation. J. Immunol. 167:1769-77
152. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, et al. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378:88-91
153. Hofstra CL, Van Ark I, Hofman G, Kool M, Nijkamp FP, et al. 1998. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J. Immunol. 161:5054-60
154. Kodama T, Matsuyama T, Kuribayashi K, Nishioka Y, Sugita M, et al. 2000. IL-18 deficiency selectively enhances allergen-induced eosinophilia in mice. J. Allergy Clin. Immunol. 105:45-53
155. Walter DM, Wong CP, DeKruyff RH, Berry GJ, Levy S, et al. 2001. Il-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyperreactivity. J. Immunol. 166:6392-98
156. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. 2001. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12:53-72
157. Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, et al. 1999. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl. Acad. Sci. USA 96:13962-66
158. Yoshimoto T, Mizutani H, Tsutsui H, Noben-Trauth N, Yamanaka K, et al. 2000. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat. Immunol. 1:132-37
159. Wild JS, Sigounas A, Sur N, Siddiqui MS, Alam R, et al. 2000. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J. Immunol. 164:2701-10
160. Kumano K, Nakao A, Nakajima H, Hayashi F, Kurimoto M, et al. 1999. Interleukin-18 enhances antigen-induced eosinophil recruitment into the mouse airways. Am. J. Respir. Crit. Care Med. 160:873-78
161. Helmby H, Takeda K, Akira S, Grencis RK. 2001. Interleukin (IL)-18 promotes the development of chronic gastrointestinal helminth infection by downregulating IL-13. J. Exp. Med. 194:355-64
162. Hoffmann KF, Caspar P, Cheever AW, Wynn TA. 1998. IFN-γ, IL-12, and TNF-α are required to maintain reduced liver pathology in mice vaccinated with Schistosoma mansoni eggs and IL-12. J. Immunol. 161:4201-10
163. Henri S, Chevillard C, Mergani A, Paris P, Gaudart J, et al. 2002. Cytokine regulation of periportal fibrosis in humans infected with schistosomamansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. J. Immunol. 169:929-36
164. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765
165. Grunig G, Corry DB, Leach MW, Seymour BW, Kurup VP, et al. 1997. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 185:1089-99
166. Wynn TA, Morawetz R, Scharton-Kersten T, Hieny S, Morse H, et al. 1997. Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1- and T helper cell 2-type cytokine responses in vivo. J. Immunol. 159:5014-23
167. Wynn TA, Cheever AW, Williams ME, Hieny S, Caspar P, et al. 1998. IL-10 regulates liver pathology in acute murine schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J. Immunol. 160:5000-8
168. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. 2001. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J. Immunol. 167:7017-26
169. Stampfli MR, Cwiartka M, Gajewska BU, Alvarez D, Ritz SA, et al. 1999. Interleukin-10 gene transfer to the airway regulates allergic mucosal sensitization in mice. Am. J. Respir. Cell Mol. Biol. 21:586-96
170. Umetsu DT, DeKruyff RH. 1999. Interleukin-10: the missing link in asthma regulation? Am. J. Respir. Cell Mol. Biol. 21:562-63
171. Wills-Karp M, Santeliz J, Karp CL. 2001. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat. Rev. Immunol. 1:69-75
172. Yazdanbakhsh M, Kremsner PG, van Ree R. 2002. Allergy, parasites, and the hygiene hypothesis. Science 296:490-94
173. van den Biggelaar AHJ, van Ree R, Rodrigues LC, Lell B, Deelder AM, et al. 2000. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 356:1723-27
174. Tournoy KG, Kips JC, Pauwels RA. 2000. Endogenous interleukin-10 suppresses allergen-induced airway inflammation and nonspecific airway responsiveness. Clin. Exp. Allergy 30:775-83
175. Akbari O, DeKruyff RH, Umetsu DT. 2001. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2:725-31
176. Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, et al. 2002. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. 8:625-29
177. Makela MJ, Kanehiro A, Borish L, Dakhama A, Loader J, et al. 2000. IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. Proc. Natl. Acad. Sci. USA 97:6007-12
178. Justice JP, Shibata Y, Sur S, Mustafa J, Fan M, et al. 2001. IL-10 gene knockout attenuates allergen-induced airway hyperresponsiveness in C57BL/6 mice. Am. J. Physiol. Lung Cell Mol. Physiol. 280:L363-68
179. Yang X, Wang S, Fan Y, Han X. 2000. IL-10 deficiency prevents IL-5 overproduction and eosinophilic inflammation in a murine model of asthma-like reaction. Eur. J. Immunol. 30:382-91
180. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. 2000. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J. Immunol. 164:2585-91
181. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, et al. 2000. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. Pharmacol. Exp. Ther. 292:988-94
182. Booth BW, Adler KB, Bonner JC, Tournier F, Martin LD. 2001. Interleukin-13 induces proliferation of human airway epithelial cells in vitro via a mechanism mediated by transforming growth factor-alpha. Am. J. Respir. Cell Mol. Biol. 25:739-43
183. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, et al. 1996. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J. Biol. Chem. 271:29265-70
184. Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, et al. 1996. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J. Biol. Chem. 271:16921-26
185. Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, et al. 1996. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA 93:497-501
186. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G. 1993. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 12:2663-70
187. Zhang JG, Hilton DJ, Willson TA, McFarlane C, Roberts BA, et al. 1997. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J. Biol. Chem. 272:9474-80
188. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, et al. 1993. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261:472-75
189. Abbas AK, Murphy KM, Sher A. 1996. Functional diversity of helper T lymphocytes. Nature 383:787-93